ArticleScientific reports2025
Umbilical cord-derived exosomes alleviate spinal cord injury by regulating microglial polarization through miR-340-5p-mediated modulation of the JAK/STAT3 signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Injectable Hydrogel Loaded With Umbilical Cord Blood-Derived Exosomes Promotes Periodontal Bone Regeneration via the TLR4/NF-κB Signalling Pathway.Journal of cellular and molecular medicine · 2026Article
- A dual-functional engineered exosome-laden hydrogel redirects endogenous neural stem cell fate for spinal cord injury repair.Bioactive materials · 2026Article
- Review
- Role of the miR-340-5p/IRF1/USP18 Axis in Neuroinflammation Associated with Epilepsy.Neurochemical research · 2026Article
- LEP Knockdown Improves Functional Recovery After Spinal Cord Injury and Potentially Regulates Microglial Polarization via JAK-STAT Signaling Pathway.Neuromolecular medicine · 2026Article
- The role of natural and engineered exosomes in repairing damage to the nervous system.Journal of nanobiotechnology · 2026Review
- Dynamic activation of lytic cell death-related programs identifies CD14 as a candidate hub gene associated with secondary injury after spinal cord injury.Frontiers in immunology · 2026Article
- Review
- Extracellular vesicle-based therapeutic strategies for spinal cord injury.Extracellular vesicles and circulating nucleic acids · 2026Review
- Exosome-derived ncRNAs and proteins: inflammation regulatory mechanisms and biomarker potential in spinal cord injury.Frontiers in molecular biosciences · 2026Review
- Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Strategy for Spinal Cord Injury.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Spinal cord injury (SCI) is a condition of the central nervous system, results in impairments in both sensory and motor functions. Presently, there exists a deficiency in efficacious therapies. Nonetheless, employing exosomes, a derivative of human umbilical cord mesenchymal stem cells (hucMSCs), is proven to be a successful approach in treating SCI, yet the exact way they function is still not well understood. Our research involved conducting a laminectomy on mice's thoracic T8-T10 and subsequently striking the revealed spinal cord using an altered Allen's weight descending apparatus (8 g, height 50 mm, 8 g × 50 mm) to create a model for SCI animals. To create a model of BV2 inflammation, BV2 cells underwent a 24-hour treatment with 1 µg/mL LPS. The expression of related genes and proteins was identified using RT‒qPCR and western blot. ELISA, immunofluorescence staining, and HE staining were employed to assess the polarization of BV2 cells and spinal cord tissue damage in mice. The research indicated that exosomes originating from hucMSCs are capable of markedly hindering the M1 polarization in BV2 cells, diminishing inflammation, and lessening the progression of SCI in vivo. From a mechanistic standpoint, exosomes originating from hucMSCs suppressed iNOS and CD16 levels, enhanced Arg1 and CD206 expression, lessened BV2 cells' M1 polarization, and concurrently suppressed LPS-triggered inflammatory cytokines IL-6, TNF-α, and IL-1β, ultimately easing LPS-triggered inflammation and mitigating SCI progression. The impact of exosomes derived from hucMSCs primarily resulted from the enhancement of miR-340-5p expression, which in turn suppressed the JAK/STAT3 signaling pathway. The findings of our research indicate that exosomes derived from hucMSCs could represent an innovative approach in treating SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.